Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Richard J. Lin, Soo Jung Kim, Samantha Brown, Danielle M Hanley, Danielle E Engstler, Ioannis Politikos, Boglarka Gyurkocza, Roni Tamari, Esperanza B. Papadopoulos, Amethyst Saldia, Yetunde Aremu, Aaron D. Goldberg, Mark Blaine Geyer, Eytan M. Stein, Miguel Angel Perales, Beatriz Korc-Grodzicki, Sean M. Devlin, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 686.

https://doi.org/10.1182/blood-2024-207934

Published: 2024

Journal Articles

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Charlotte FM Hughes, Richard J. Lin, Sean M. Devlin, Brian C. Shaffer, Ann A. Jakubowski, Vishwamber Talla, Amethyst Saldia, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Sergio A. Giralt, Elena Maryamchik, Miguel-Angel Perales, Roni Tamari

Blood (2024) 144 (Supplement 1): 267.

https://doi.org/10.1182/blood-2024-198799

Published: 2024

Journal Articles

Optimized Double-Unit Cord Blood Transplantation Mitigates Transplant-Related Mortality Resulting in High Progression-Free Survival in Adults with Hematologic Malignancies

Ioannis Politikos, Sean M. Devlin, Stephanie Chinapen, Sean Quach, Parastoo B. Dahi, Boglarka Gyurkocza, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Roni Tamari, Andromachi Scaradavou, Juliet N Barker

Blood (2023) 142 (Supplement 1): 4916.

https://doi.org/10.1182/blood-2023-190528

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial

Alina Markova, Esperanza B. Papadopoulos, Stephen Dusza, Jelena Ostojić, Rizi Ai, Tara Maier, Mario Lacouture, Roni Tamari, Boglarka Gyurkocza, Brian C. Shaffer, Michael Scordo, Miguel-Angel Perales, Andrew Harris, Doris M. Ponce

Blood (2023) 142 (Supplement 1): 777.

https://doi.org/10.1182/blood-2023-182198

Published: 2023

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

Analysis of 3,843 Unrelated Donors (URD) for 455 Allograft Candidates Reveals Low URD Availability with Marked Racial/ Ethnic Disparities: Major Implications for Transplant Center & Registry Operations

Warren B Fingrut, Eric Davis, Anne Archer, Samantha Brown, Sean M. Devlin, Melissa Nhaissi, Candice Rapoport, Stephanie Chinapen, Amanda Kelly, Deborah Wells, Andromachi Scaradavou, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Ioannis Politikos, Brian C. Shaffer, Juliet N Barker

Blood (2023) 142 (Supplement 1): 5114.

https://doi.org/10.1182/blood-2023-180439

Published: 2023

Journal Articles

Post-Transplant Pain and Paralysis: Neurologic Amyotrophy As an Atypical Cause of Shoulder Dysfunction Following Hematopoietic Stem Cell Transplant

Chanel Davidoff, Katarzyna Ibanez, Sinchun Hwang, Ilan Goldstein, Darren R. Feldman, Boglarka Gyurkocza, Sergio A. Giralt, Ioannis Politikos, Doris M. Ponce, Michael Scordo, Grigory Syrin, Gunjan L. Shah, Christian M. Custodio, Franchesca Konig

Blood (2023) 142 (Supplement 1): 6978.

https://doi.org/10.1182/blood-2023-189328

Published: 2023

Journal Articles

Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd

Toshihisa Satta, Esperanza B. Papadopoulos, Boglarka Gyurkocza, Pamela Susman, Amandeep Singh, Marco Calafiore, Sergio A. Giralt, Miguel-Angel Perales, Jianmin Chen, Simon Li, Jonathan U. Peled, Marcel R.M. van den Brink, Alan M. Hanash, Doris M. Ponce

Blood (2023) 142 (Supplement 1): 7019.

https://doi.org/10.1182/blood-2023-181269

Published: 2023

Journal Articles

High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

Ioannis Politikos, Warren B Fingrut, Samantha Brown, Stephanie Chinapen, Sean Quach, Parastoo B. Dahi, Boglarka Gyurkocza, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Roni Tamari, Miguel-Angel Perales, Andromachi Scaradavou, Juliet N Barker

Blood (2023) 142 (Supplement 1): 2209.

https://doi.org/10.1182/blood-2023-190836

Published: 2023

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Shlomo Elias, Moneeza Walji, Samantha Brown, Sean M. Devlin, Esperanza B. Papadopoulos, Ann A Jakubowski, Doris M Ponce, James W. Young, Sergio A Giralt, Miguel-Angel Perales, Brian C. Shaffer, Parastoo B. Dahi, Richard J. Lin, Christina Cho, Roni Tamari, Melody Smith, Boglarka Gyurkocza

Blood (2022) 140 (Supplement 1): 10627–10628.

https://doi.org/10.1182/blood-2022-170088

Published: 2022

Journal Articles

Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations

Blood (2022) 140 (Supplement 1): 4759–4761.

https://doi.org/10.1182/blood-2022-159303

Published: 2022

Journal Articles

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Blood (2022) 140 (Supplement 1): 2137–2139.

https://doi.org/10.1182/blood-2022-157193

Published: 2022

Journal Articles

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Blood (2021) 138 (Supplement 1): 1791.

https://doi.org/10.1182/blood-2021-148497

Published: 2021

Journal Articles

Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of "Donors for All"

Warren Fingrut, Ioannis Politikos, Eric Davis, Stephanie Chinapen, Kristine Naputo, Christina Cho, Sergio A Giralt, Boglarka Gyurkocza, Ann A Jakubowski, Esperanza B Papadopoulos, Miguel-Angel Perales, Doris M Ponce, Andromachi Scaradavou, Brian C Shaffer, Juliet N Barker

Blood (2021) 138 (Supplement 1): 423.

https://doi.org/10.1182/blood-2021-147329

Published: 2021

Journal Articles

Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137749

Published: 2020

Journal Articles

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134624

Published: 2020

Journal Articles

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-137552

Published: 2020

Journal Articles

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-134948

Published: 2020

NARROW

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Optimized Double-Unit Cord Blood Transplantation Mitigates Transplant-Related Mortality Resulting in High Progression-Free Survival in Adults with Hematologic Malignancies

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Analysis of 3,843 Unrelated Donors (URD) for 455 Allograft Candidates Reveals Low URD Availability with Marked Racial/ Ethnic Disparities: Major Implications for Transplant Center & Registry Operations

Post-Transplant Pain and Paralysis: Neurologic Amyotrophy As an Atypical Cause of Shoulder Dysfunction Following Hematopoietic Stem Cell Transplant

Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd

High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of "Donors for All"

Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only